Search Results - david+eisenberg

3 Results

Sort By:

Compounds that Disaggregate Alzheimer's Disease-Associated Fibrils of Tau Protein (UCLA Case No. 2022-145, 2025-329)

UCLA researchers in the Department of Biological Chemistry, Chemistry and Biochemistry developed a new tau-inhibiting seven residue peptide and conjugated it to magnetic nanoparticles for the treatment of Alzheimer’s disease. These compounds disaggregate pathogenic tau amyloid fibrils at atomic resolution, restore normal neuronal function, and...

Published: 11/19/2025 | Inventor(s): David Eisenberg, Ke Hou

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

2019-701 PEPTIDE-BASED INHIBITORS THAT BLOCK AGGREGATION, SEEDING AND CROSS-SEEDING OF AMYLOID BETA AND TAU

UCLA researchers in the Department of Chemistry and Biochemistry have developed novel therapeutics for Alzhiemer’s Disease and other tauoapathies. BACKGROUND:Alzhiemer’s Disease (AD) is a severe neurodegenerative disease characterized by deterioration of the brain cells and loss of multiple cognitive functions. Although AD is the most...

Published: 7/17/2025 | Inventor(s): David Eisenberg, Paul Seidler

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics > CNS and Neurology

2016-694 INHIBITION OF THE AGGREGATION OF TRANSTHYRETIN BY SPECIFIC BINDING OF PEPTIDES TO AGGREGATION-DRIVING SEGMENTS

Inhibition of the Aggregation of Transthyretin by Specific Binding of Peptides to Aggregation-Driving SegmentsSUMMARYUCLA researchers from the Department of Chemistry and Biochemistry have developed a novel process to inhibit amyloid aggregation of Transthyretin, which is associated with three debilitating disorders including senile systemic amyloidosis...

Published: 7/17/2025 | Inventor(s): David Eisenberg, Lorena Saelices Gomez

Keywords(s): Cardiovascular, Cns, Genetic Disease, Hematology, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Cardiovascular, Therapeutics > Hematology, Therapeutics > CNS and Neurology